TY - JOUR
T1 - A genome-wide association study on liver stiffness changes during hepatitis c virus infection cure
AU - Corma-Gómez, Anaïs
AU - Macías, Juan
AU - Rivero, Antonio
AU - Rivero-Juarez, Antonio
AU - de los Santos, Ignacio
AU - Reus-Bañuls, Sergio
AU - Morano, Luis
AU - Merino, Dolores
AU - Palacios, Rosario
AU - Galera, Carlos
AU - Fernández-Fuertes, Marta
AU - González-Serna, Alejandro
AU - de Rojas, Itziar
AU - Ruiz, Agustín
AU - Sáez, María E.
AU - Real, Luis M.
AU - Pineda, Juan A.
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/8
Y1 - 2021/8
N2 - Liver stiffness (LS) at sustained virological response (SVR) after direct-acting antivirals (DAA)-based therapy is a predictor of liver events in hepatitis C virus (HCV)-infected patients. The study aim was to identify genetic factors associated with LS changes from the moment of starting anti-HCV therapy to SVR. This prospective study included HCV-infected patients from the GEHEP-011 cohort who achieved SVR with DAA-based therapy, with LS pre-treatment ≥9.5 kPa and LS measurement available at SVR. Plink and Magma software were used to carry out genome-wide single-nucleotide polymorphism (SNP)-based and gene-based association analyses, respectively. The ShinyGO application was used for exploring enrichment in Gene Ontology (GO) categories for biological processes. Overall, 242 patients were included. Median (quartile 1, quartile 3) LS values at pre-treatment and at SVR were 16.8 (12, 28) kPa and 12.0 (8.5, 19.3) kPa, respectively. Thirty-five SNPs and three genes reached suggestive association with LS changes from the moment of starting anti-HCV therapy to SVR. GO categories related to DNA packaging complex, DNA conformation change, chromosome organization and chromatin organization were significantly enriched. Our study reports possible genetic factors associated with LS changes during HCV-infection cure. In addition, our results suggest that processes related to DNA conformation are also involved in these changes.
AB - Liver stiffness (LS) at sustained virological response (SVR) after direct-acting antivirals (DAA)-based therapy is a predictor of liver events in hepatitis C virus (HCV)-infected patients. The study aim was to identify genetic factors associated with LS changes from the moment of starting anti-HCV therapy to SVR. This prospective study included HCV-infected patients from the GEHEP-011 cohort who achieved SVR with DAA-based therapy, with LS pre-treatment ≥9.5 kPa and LS measurement available at SVR. Plink and Magma software were used to carry out genome-wide single-nucleotide polymorphism (SNP)-based and gene-based association analyses, respectively. The ShinyGO application was used for exploring enrichment in Gene Ontology (GO) categories for biological processes. Overall, 242 patients were included. Median (quartile 1, quartile 3) LS values at pre-treatment and at SVR were 16.8 (12, 28) kPa and 12.0 (8.5, 19.3) kPa, respectively. Thirty-five SNPs and three genes reached suggestive association with LS changes from the moment of starting anti-HCV therapy to SVR. GO categories related to DNA packaging complex, DNA conformation change, chromosome organization and chromatin organization were significantly enriched. Our study reports possible genetic factors associated with LS changes during HCV-infection cure. In addition, our results suggest that processes related to DNA conformation are also involved in these changes.
KW - Direct-acting antivirals
KW - GWAS
KW - Hepatitis C virus infection
KW - Liver stiffness
KW - Polymorphisms
KW - Sustained virological response
UR - https://www.scopus.com/pages/publications/85114158807
UR - https://www.scopus.com/pages/publications/85114158807#tab=citedBy
U2 - 10.3390/diagnostics11081501
DO - 10.3390/diagnostics11081501
M3 - Article
AN - SCOPUS:85114158807
SN - 2075-4418
VL - 11
JO - Diagnostics
JF - Diagnostics
IS - 8
M1 - 1501
ER -